Scientists hunt for clues to drug resistance in tough colorectal cancer
NCT ID NCT07617610
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study looks at why a specific type of advanced colorectal cancer (with a BRAF V600E mutation) becomes resistant to standard targeted therapy. Researchers will collect tumor tissue, blood, and stool samples from 30 patients before treatment and when the disease progresses. They will also grow mini-tumors in the lab to test new ways to overcome resistance. The goal is to gather knowledge that could lead to more effective treatments in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bürgerspital Solothurn
RECRUITINGSolothurn, 4500, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HFR Freiburg - Kantonsspital
RECRUITINGVillars-sur-Glâne, 1752, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HOCH Health Ostschweiz - Kantonsspital St. Gallen
RECRUITINGSankt Gallen, 9007, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Inselspital Bern
RECRUITINGBern, 3010, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kantonsspital Aarau
RECRUITINGAarau, CH-5000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Baden
RECRUITINGBaden, 5404, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Graubünden
RECRUITINGChur, 7000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Winterthur
RECRUITINGWinterthur, 8004, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Luzerner Kantonsspital
RECRUITINGLucerne, 6004, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Claraspital
RECRUITINGBasel, 4058, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitaetsspital Basel
RECRUITINGBasel, CH-4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Zürich USZ
RECRUITINGZurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Longitudinal translational sampling (tumor tissue, blood, stool) and patient-derived organoids
What this could lead to
If successful, this could reveal why current treatments stop working and point toward new drug combinations to overcome resistance.
What could go wrong
This is an early-stage observational study with only 30 participants, so findings may not apply to all patients. It does not test a new treatment directly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.